3rd Quarter - Report

BIOTECHNOLOGY INNOVATION ORGANIZATION for BIOTECHNOLOGY INNOVATION ORGANIZATION

Firm
Client
Income
—
Expenses
$2,100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

17 issue areas, each in the filer's own words, with who lobbied on it and where.

Agriculture AGR

EPA Regulations on Agricultural Biotechnology --Pesticide Registration Improvement Act Reauthorization Livestock Cloning/Product Labeling --Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals --Labeling --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 ---Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology --H.R. 1599: Safe and Accurate Food Labeling Act of 2015 --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Funding for the USDA --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Foreign Agricultural Biotechnology Laws and Regulations --Asynchrony of International Approvals --China Biotechnology Regulations --EU Ag-Biotech Policies and Regulations Potential Regulation of New Genetic Modification Technologies USDA/APHIS Agricultural Biotechnology Regulations --Efficient Science-Based Review of Biotech Products International Treaty on Plant Genetic Resources Review of the Federal Coordinated Framework for Biotechnology Products

LobbyistCovered position, as disclosed
BRIAN T BAENIG New LA,Sen Wellstone,5-1-1998-12-31-02;Staff, Sen Jud. Cmt,7-1-03-5-31-05; Sr Policy Adv,Sen Leahy,6-1-05-9-31-09; Dep Staff Dir., Sen Ag Cmt.,10-1-09-2-28-11; Dep Undersec.,USDA, 3-1-11-9-30-11; Asst Sec,USDA 10-1-11-8-31-13; CoS, USDA,9-1-13-8-31-15
TOM DILENGE —
JEANNE HAGGERTY —
TRACEY LATURNER —
DANA MAURICE O'BRIEN —
MATTHEW O'MARA —

Contacted: Environmental Protection Agency (EPA); Agriculture, Dept of (USDA); U.S. Trade Representative (USTR); Office of Science & Technology Policy (OSTP); SENATE; Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Patent & Trademark Office (PTO); Council on Environmental Quality (CEQ); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: H.R. 3049 (114th), S. 1800 (114th), H.R. 1599 (114th)

Budget/Appropriations BUD

Funding for the USDA --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Funding for FDA --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Funding for the National Institutes of Health --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Funding for Centers for Disease Control and Prevention Vaccine Programs --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Funding for Renewable Chemicals/Bio-based Products --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 --H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016 --Implementation of the Agricultural Act of 2014, Section 9003 Funding for Biofuels --H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016 --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Sequestration of PDUFA Fees --S. 1413: FDA User Fee Protection Act --HR 2725: Food and Drug Administration Safety over Sequestration Act of 2015

Contacted: Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Office of Management & Budget (OMB); Environmental Protection Agency (EPA); Council on Environmental Quality (CEQ); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); SENATE

Bills named: H.R. 3020 (114th), H.R. 2028 (114th), S. 1695 (114th), S. 1413 (114th), S. 1800 (114th), H.R. 3049 (114th), H.R. 2725 (114th)

Animals ANI

Livestock Cloning/Product Labeling --Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals --Labeling --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 ---Amendment on GE Salmon Labeling

LobbyistCovered position, as disclosed
BRIAN T BAENIG New LA,Sen Wellstone,5-1-1998-12-31-02;Staff, Sen Jud. Cmt,7-1-03-5-31-05; Sr Policy Adv,Sen Leahy,6-1-05-9-31-09; Dep Staff Dir., Sen Ag Cmt.,10-1-09-2-28-11; Dep Undersec.,USDA, 3-1-11-9-30-11; Asst Sec,USDA 10-1-11-8-31-13; CoS, USDA,9-1-13-8-31-15
JEANNE HAGGERTY —
TRACEY LATURNER —
DANA MAURICE O'BRIEN —
MATTHEW O'MARA —

Contacted: Natl Institutes of Health (NIH); Office of Management & Budget (OMB); SENATE; Environmental Protection Agency (EPA); Patent & Trademark Office (PTO); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Agriculture, Dept of (USDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Council on Environmental Quality (CEQ)

Bills named: S. 1800 (114th), H.R. 3049 (114th)

Science/Technology SCI

Synthetic Biology --H.R. 591: Engineering Biology Research and Development Act

LobbyistCovered position, as disclosed
TOM DILENGE —
JEANNE HAGGERTY —
DANA MAURICE O'BRIEN —

Contacted: Health Resources & Services Administration (HRSA); Environmental Protection Agency (EPA); Council on Environmental Quality (CEQ); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Agriculture, Dept of (USDA); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH)

Bills named: H.R. 591 (114th)

Trade (domestic/foreign) TRD

Biosimilars --Colombia Biologics Regulations Foreign Agricultural Biotechnology Laws and Regulations --Asynchrony of International Approvals --China Biotechnology Regulations --EU Ag Biotech Policies and Regulations TransPacific Partnership --Data and Intellectual Property Protections for Pharmaceuticals --Regulatory Transparency Transatlantic Trade and Investment Partnership --Intellectual Property Issues --Regulatory Harmonization International Treaty on Plant Genetic Resources Intellectual Property International Enforcement --India

LobbyistCovered position, as disclosed
JOSEPH DAMOND —
TOM DILENGE —
CHARLES H FRITTS —
JEANNE HAGGERTY —
NICK MAGALLANES New LC/LA, Sen. Alexander, 1-19-10-3-1-12; LA, Rep. Terry, 4-1-12-3-16-14; Staff Member, Energy & Commerce Cmt., 12-31-12-3-16-14; Health Policy Adv., Rep. Rodgers, 3-17-14-9-18-15; Sr. Adv., House Rep. Conf., 9-30-14-9-18-15
DANA MAURICE O'BRIEN —
MATTHEW O'MARA —
DERRICK M WHITE —

Contacted: Patent & Trademark Office (PTO); Agriculture, Dept of (USDA); Office of Management & Budget (OMB); Food & Drug Administration (FDA); SENATE; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Council on Environmental Quality (CEQ); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Office of Science & Technology Policy (OSTP); Health Resources & Services Administration (HRSA)

Taxation/Internal Revenue Code TAX

Renewable Chemicals/Bio-based Products --Expansion of Master Limited Partnerships to Renewable Chemicals --New Production Tax Credit --S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act --H.R. 2833/S.1656: Master Limited Partnerships Parity Act of 2015 Biofuels --Production Tax Credit Extension --S.2089: American Energy Innovation Act Research & Development Tax Credit Reforms --Extension --Permanency --Refundable R&D Credit --H.R.880: To amend the Internal Revenue Code to make permanent the credit for increasing research activities --S. 341: Start-up Jobs and Innovation Act --S. 537: COMPETE Act Capital Formation Investment Incentives --Reform of Capital Gains Rules --Reform of Net Operating Loss Rules --Reform of Passive Loss Rules --S. 341: Start-up Jobs and Innovation Act --S. 537: COMPETE Act --H.R. 2179: PARTNER Act Tax Reform --Innovation Box/Patent Box Orphan Drug Act Tax Credit Inversions --H.R. 2995/S.1910: Department of Financial Services and Related Agencies Appropriations Act for FY 2016 Antibiotic & Diagnostic Tax Credit --H.R. 3539: Antibiotic & Diagnostic Innovation Act

Contacted: SENATE; Council on Environmental Quality (CEQ); Office of Science & Technology Policy (OSTP); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Agriculture, Dept of (USDA); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 2089 (114th), S. 1656 (114th), S. 537 (114th), H.R. 2833 (114th), H.R. 3084 (114th), H.R. 2995 (114th), H.R. 2179 (114th), S. 1267 (114th), S. 341 (114th), H.R. 3539 (114th), H.R. 880 (114th), S. 1910 (114th)

Copyright/Patent/Trademark CPT

Patent Reform --H.R. 9: Innovation Act --S.1137: Protecting American Talent and Entrepreneurship Act of 2015 --Implementation of the America Invents Act of 2011 TransPacific Partnership --Data and Intellectual Property Protections for Pharmaceuticals --Regulatory Transparency Transatlantic Trade and Investment Partnership --Intellectual Property Issues Drug Patent Settlements --S.1137: Protecting American Talent and Entrepreneurship Act of 2015 --S. 2019: Preserve Access to Affordable Generics Act of 2015 Inter Partes Review --Implementation of the American Invents Act of 2011 --S. 632: STRONG Patents Act --S. 1137: Protecting American Talent and Entrepreneurship Act of 2015 --H.R. 9: Innovation Act Intellectual Property International Enforcement --India

LobbyistCovered position, as disclosed
JOSEPH DAMOND —
TOM DILENGE —
CHARLES H FRITTS —
JAMIE GREGORIAN —
JEANNE HAGGERTY —
A. CATHARINE HARRIS —
TRACEY LATURNER —
NICK MAGALLANES New LC/LA, Sen. Alexander, 1-19-10-3-1-12; LA, Rep. Terry, 4-1-12-3-16-14; Staff Member, Energy & Commerce Cmt., 12-31-12-3-16-14; Health Policy Adv., Rep. Rodgers, 3-17-14-9-18-15; Sr. Adv., House Rep. Conf., 9-30-14-9-18-15
DANA MAURICE O'BRIEN —
HANSJORG SAUER —
ANNA KATHERINE WEINSTEIN —
DERRICK M WHITE —

Contacted: Natl Institutes of Health (NIH); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Office of Management & Budget (OMB); Office of Science & Technology Policy (OSTP); Agriculture, Dept of (USDA); Council on Environmental Quality (CEQ); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Environmental Protection Agency (EPA); Health Resources & Services Administration (HRSA); Patent & Trademark Office (PTO)

Bills named: S. 632 (114th), S. 2019 (114th), H.R. 9 (114th), S. 1137 (114th)

Health Issues HCR

Biosimilars --Biosimilar User Fee Act Implementation --Coding --Colombia Biologics Regulations --Implementation of Affordable Care Act --Interchangeability and Pharmacy Substitution --Naming --Reimbursement Policy Funding for Centers for Disease Control and Prevention Vaccine Programs --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Vaccine Access/Financing 340B Drug Pricing Program --Program Implementation & Oversight --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Medicaid Pricing and Rebates --Average Manufacturer Price Calculations Diagnostics and Personalized Medicine Regulation and Oversight Funding for FDA --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Biodefense Research, Development and Procurement Issues (Non-funding) TransPacific Partnership --Data and Intellectual Property Protections for Pharmaceuticals --Regulatory Transparency Transatlantic Trade and Investment Partnership --Intellectual Property Issues --Regulatory Harmonization Reimbursement for Innovative Products --Medicare Part D Prescription Drug Program --Medicare Part B Physician-Administered Products Sequestration of PDUFA Fees --S. 1413: FDA User Fee Protection Act --HR 2725: Food and Drug Administration Safety over Sequestration Act of 2015 Drug Evaluation and Review --Compassionate Use/Expanded Access --Implementation of the FDA Safety and Innovation Act Orphan Drug Act Tax Credit Senate Innovation for Healthier Americans Initiative --Biomarkers and Regulatory Science Improvements --Combination Products --Communication with Healthcare Professionals --Expanded Access to Investigational Drugs --Expedited Pathways --FDA Hiring Flexibility --FDA Management and Financial Accountability --Information Disclosures --Innovation Incentives --Longitudinal Study of Chronic Diseases --Patient Access to Approved Drugs --Patient-Focused Drug Development --Use of Real-World Evidence --Vaccine and Anti-Microbial Resistance Product Development and Incentives --PATH Act (Senate Discussion Draft) House 21st Century Cures Initiative --Vaccine and Anti-Microbial Resistance Product Development and Incentives --ADAPT Act (House Discussion Draft) --Biomarkers and Regulatory Science Improvements --Communication with Healthcare Professionals --Expanded Access to Investigational Drugs --Expedited Pathways --FDA Hiring Flexibility --FDA Management and Financial Accountability --Innovation Incentives --Longitudinal Study of Chronic Diseases --Patient Access to Approved Drugs --Patient-Focused Drug Development --Use of Real-World Evidence Vaccines and Infectious Diseases - General Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Government Price Reporting --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Gene Editing Technologies --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 -----Report Language on Heritable Genetic Modification Restriction NIH Precision Medicine Initiative Antibiotic & Diagnostic Tax Credit --H.R. 3539: Antibiotic & Diagnostic Innovation Act

LobbyistCovered position, as disclosed
PHYLLIS ARTHUR —
KELLY CAPPIO —
JOSEPH DAMOND —
TOM DILENGE —
ANDREW EMMETT —
ELIZABETH CARTIER ESHAM —
CHARLES H FRITTS —
JAMIE GREGORIAN —
JEANNE HAGGERTY —
A. CATHARINE HARRIS —
ERIN ESTEY HERTZOG —
KATHLEEN HOLCOMBE —
TRACEY LATURNER —
NICK MAGALLANES LC/LA, Sen. Alexander, 1-19-10-3-1-12; LA, Rep. Terry, 4-1-12-3-16-14; Staff Member, Energy & Commerce Cmt., 12-31-12-3-16-14; Health Policy Adv., Rep. Rodgers, 3-17-14-9-18-15; Sr. Adv., House Rep. Conf., 9-30-14-9-18-15
SHELLY MUI-LIPNIK —
LAUREL TODD —
AMY WALKER —
ANNA KATHERINE WEINSTEIN —
DERRICK M WHITE —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Office of Science & Technology Policy (OSTP); Council on Environmental Quality (CEQ); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Environmental Protection Agency (EPA); Agriculture, Dept of (USDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3049 (114th), S. 1695 (114th), H.R. 3020 (114th), S. 1800 (114th), S. 1413 (114th), H.R. 2725 (114th), H.R. 3539 (114th)

Small Business SMB

Sarbanes Oxley Section 404 (b) --Exemption for Emerging Companies Capital Formation Investment Incentives --Reform of Capital Gains Rules --Reform of Net Operating Loss Rules --Reform of Passive Loss Rules --S. 341: Start-up Jobs and Innovation Act --S. 537: COMPETE Act --H.R. 2179: PARTNER Act Expansion of Exemption under SEC Regulation A --H.R. 1839: Reforming Access for Investments in Startup Enterprises (RAISE) Act Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions --Fostering Innovation Act (House Discussion Draft) XBRL Exemption for Small Public Companies --H.R. 1965: Small Company Disclosure Simplification Act Capital Market Enhancements --SEC Office of Small Business Policy Responsibilities --H.R. 1525: Disclosure Modernization and Simplification Act --H.R. 1675: Encouraging Employee Ownership Act --H.R. 1723: Small Company Simple Registration Act --H.R. 2064: Improving Access to Capital for Emerging Growth Companies Act --H.R. 2357: Accelerating Access to Capital Act

LobbyistCovered position, as disclosed
CHARLES CRAIN —
ELIZABETH CARTIER ESHAM —
CHARLES H FRITTS —
JEANNE HAGGERTY —
SHELLY MUI-LIPNIK —

Contacted: Health & Human Services, Dept of (HHS); Council on Environmental Quality (CEQ); Office of Management & Budget (OMB); Agriculture, Dept of (USDA); Food & Drug Administration (FDA); SENATE; Health Resources & Services Administration (HRSA); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Office of Science & Technology Policy (OSTP); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO)

Bills named: H.R. 2357 (114th), H.R. 1525 (114th), H.R. 1965 (114th), H.R. 1723 (114th), S. 537 (114th), H.R. 2179 (114th), H.R. 1839 (114th), S. 341 (114th), H.R. 1675 (114th), H.R. 2064 (114th)

Medicare/Medicaid MMM

Medicaid Pricing and Rebates --Average Manufacturer Price Calculations Reimbursement for Innovative Products --Medicare Part D Prescription Drug Program --Medicare Part B Physician-Administered Products House 21st Century Cures Initiative --Patient Access to Approved Drugs Senate Innovation for Healthier Americans Initiative --Patient Access to Approved Drugs Government Price Reporting --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

LobbyistCovered position, as disclosed
JAMIE GREGORIAN —
JEANNE HAGGERTY —
A. CATHARINE HARRIS —
ERIN ESTEY HERTZOG —
KATHLEEN HOLCOMBE —
NICK MAGALLANES New LC/LA, Sen. Alexander, 1-19-10-3-1-12; LA, Rep. Terry, 4-1-12-3-16-14; Staff Member, Energy & Commerce Cmt., 12-31-12-3-16-14; Health Policy Adv., Rep. Rodgers, 3-17-14-9-18-15; Sr. Adv., House Rep. Conf., 9-30-14-9-18-15
LAUREL TODD —
ANNA KATHERINE WEINSTEIN —
DERRICK M WHITE —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Council on Environmental Quality (CEQ); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); SENATE; Agriculture, Dept of (USDA); Office of Management & Budget (OMB); Environmental Protection Agency (EPA); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: S. 1695 (114th), H.R. 3020 (114th)

Chemicals/Chemical Industry CHM

Renewable Chemicals/Bio-based Products (Non-Funding) --S. 697: Chemical Safety for the 21st Century Act ----Nomenclature Usage ----Pre-market Notification Review --S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act --H.R. 2833/S.1656: Master Limited Partnerships Parity Act of 2015 --Expansion of Master Limited Partnerships to Renewable Chemicals --Implementation of the Agricultural Act of 2014, Section 9003 Funding for Renewable Chemicals/Bio-based Products --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 --H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016 --Implementation of the Agricultural Act of 2014, Section 9003

LobbyistCovered position, as disclosed
TOM DILENGE —
CHARLES H FRITTS —
JEANNE HAGGERTY —
TRACEY LATURNER —
ERICK LUTT —
DANA MAURICE O'BRIEN —
RINA SINGH —

Contacted: Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Agriculture, Dept of (USDA); Environmental Protection Agency (EPA); SENATE; Office of Science & Technology Policy (OSTP); Food & Drug Administration (FDA); Council on Environmental Quality (CEQ); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 697 (114th), H.R. 3084 (114th), S. 1800 (114th), H.R. 2028 (114th), H.R. 2833 (114th), S. 1656 (114th), H.R. 3049 (114th), S. 1267 (114th)

Consumer Issues/Safety/Products CSP

Livestock Cloning/Product Labeling --Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals --Labeling --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 ---Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology --H.R. 1599: Safe and Accurate Food Labeling Act of 2015 --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Biosimilars --Colombia Biologics Regulations --Implementation of Affordable Care Act --Interchangeability and Pharmacy Substitution --Naming USDA/APHIS Agricultural Biotechnology Regulations --Efficient Science-Based Review of Biotech Products

LobbyistCovered position, as disclosed
BRIAN T BAENIG New LA,Sen Wellstone,5-1-1998-12-31-02;Staff, Sen Jud. Cmt,7-1-03-5-31-05; Sr Policy Adv,Sen Leahy,6-1-05-9-31-09; Dep Staff Dir., Sen Ag Cmt.,10-1-09-2-28-11; Dep Undersec.,USDA, 3-1-11-9-30-11; Asst Sec,USDA 10-1-11-8-31-13; CoS, USDA,9-1-13-8-31-15
TOM DILENGE —
ANDREW EMMETT —
JEANNE HAGGERTY —
A. CATHARINE HARRIS —
KATHLEEN HOLCOMBE —
TRACEY LATURNER —
DANA MAURICE O'BRIEN —
MATTHEW O'MARA —
ANNA KATHERINE WEINSTEIN —
DERRICK M WHITE —

Contacted: SENATE; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Office of Science & Technology Policy (OSTP); Council on Environmental Quality (CEQ); HOUSE OF REPRESENTATIVES; Agriculture, Dept of (USDA); Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1800 (114th), H.R. 3049 (114th), H.R. 1599 (114th)

Energy/Nuclear ENG

Biofuels (Non-Funding) --Production Tax Credit Extension --S.2089: American Energy Innovation Act Funding for Biofuels --H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016 --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Renewable Fuel Standard (RFS) --Proposed Rule --S. 1372: American Crude Oil Export Equality Act ----Amendment to Repeal Conventional Biofuel Category of RFS --H.R. 702: A Bill to Adapt to Changing Crude Oil Market Conditions ---- Amendment to Repeal RFS

LobbyistCovered position, as disclosed
TOM DILENGE —
CHARLES H FRITTS —
JEANNE HAGGERTY —
TRACEY LATURNER —
ERICK LUTT —
DANA MAURICE O'BRIEN —
RINA SINGH —

Contacted: Health Resources & Services Administration (HRSA); SENATE; Council on Environmental Quality (CEQ); Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Office of Science & Technology Policy (OSTP); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES

Bills named: S. 1800 (114th), H.R. 3049 (114th), H.R. 702 (114th), S. 2089 (114th), H.R. 2028 (114th), S. 1372 (114th)

Food Industry (safety, labeling, etc.) FOO

Livestock Cloning/Product Labeling --Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals --Labeling --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 ----Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology --H.R. 1599: Safe and Accurate Food Labeling Act of 2015 --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

LobbyistCovered position, as disclosed
BRIAN T BAENIG LA,Sen Wellstone,5-1-1998-12-31-02;Staff, Sen Jud. Cmt,7-1-03-5-31-05; Sr Policy Adv,Sen Leahy,6-1-05-9-31-09; Dep Staff Dir., Sen Ag Cmt.,10-1-09-2-28-11; Dep Undersec.,USDA, 3-1-11-9-30-11; Asst Sec,USDA 10-1-11-8-31-13; CoS, USDA,9-1-13-8-31-15
TOM DILENGE —
JEANNE HAGGERTY —
A. CATHARINE HARRIS —
TRACEY LATURNER —
DANA MAURICE O'BRIEN —
MATTHEW O'MARA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA); Council on Environmental Quality (CEQ); Food & Drug Administration (FDA); Agriculture, Dept of (USDA)

Bills named: H.R. 1599 (114th), H.R. 3049 (114th), S. 1800 (114th)

Fuel/Gas/Oil FUE

Biofuels (Non-Funding) --Production Tax Credit Extension --S.2089: American Energy Innovation Act Funding for Biofuels --H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016 --H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016 Renewable Fuel Standard (RFS) --Proposed Rule --S. 1372: American Crude Oil Export Equality Act ----Amendment to Repeal Conventional Biofuel Category of RFS --H.R. 702: A Bill to Adapt to Changing Crude Oil Market Conditions ----Amendment to Repeal RFS

LobbyistCovered position, as disclosed
TOM DILENGE —
CHARLES H FRITTS —
JEANNE HAGGERTY —
TRACEY LATURNER —
ERICK LUTT —
DANA MAURICE O'BRIEN —
RINA SINGH —

Contacted: Patent & Trademark Office (PTO); SENATE; Office of Management & Budget (OMB); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Agriculture, Dept of (USDA); Council on Environmental Quality (CEQ); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP)

Bills named: H.R. 2028 (114th), S. 1800 (114th), H.R. 3049 (114th), H.R. 702 (114th), S. 1372 (114th), S. 2089 (114th)

Homeland Security HOM

Biodefense Research, Development and Procurement Issues (Non-funding) Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Combating Antibiotic-Resistant Bacteria (CARB) Initiative --PATH Act (Senate Discussion Draft/Innovation for Healthier Americans Initiative) --ADAPT Act (House Discussion Draft/21st Century Cures Initiative)

LobbyistCovered position, as disclosed
PHYLLIS ARTHUR —
KELLY CAPPIO —
TOM DILENGE —
ANDREW EMMETT —
ELIZABETH CARTIER ESHAM —
JEANNE HAGGERTY —
TRACEY LATURNER —
NICK MAGALLANES New LC/LA, Sen. Alexander, 1-19-10-3-1-12; LA, Rep. Terry, 4-1-12-3-16-14; Staff Member, Energy & Commerce Cmt., 12-31-12-3-16-14; Health Policy Adv., Rep. Rodgers, 3-17-14-9-18-15; Sr. Adv., House Rep. Conf., 9-30-14-9-18-15
AMY WALKER —
ANNA KATHERINE WEINSTEIN —
DERRICK M WHITE —

Contacted: Health Resources & Services Administration (HRSA); Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Agriculture, Dept of (USDA); Food & Drug Administration (FDA); SENATE; Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Council on Environmental Quality (CEQ)

Bills named: S. 1695 (114th), H.R. 3020 (114th)

Medical/Disease Research/Clinical Labs MED

NIH Precision Medicine Initiative Funding for National Institutes of Health --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016 Biodefense Research, Development and Procurement Issues (Non-funding) House 21st Century Cures Initiative --Longitudinal Study of Chronic Diseases Senate Innovation for Healthier Americans Initiative --Longitudinal Study of Chronic Diseases Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative --H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

LobbyistCovered position, as disclosed
PHYLLIS ARTHUR —
KELLY CAPPIO —
TOM DILENGE —
ANDREW EMMETT —
ELIZABETH CARTIER ESHAM —
JAMIE GREGORIAN —
JEANNE HAGGERTY —
KATHLEEN HOLCOMBE —
TRACEY LATURNER —
NICK MAGALLANES New LC/LA, Sen. Alexander, 1-19-10-3-1-12; LA, Rep. Terry, 4-1-12-3-16-14; Staff Member, Energy & Commerce Cmt., 12-31-12-3-16-14; Health Policy Adv., Rep. Rodgers, 3-17-14-9-18-15; Sr. Adv., House Rep. Conf., 9-30-14-9-18-15
AMY WALKER —
ANNA KATHERINE WEINSTEIN —

Contacted: Office of Science & Technology Policy (OSTP); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); SENATE; U.S. Trade Representative (USTR); Council on Environmental Quality (CEQ); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Agriculture, Dept of (USDA); Food & Drug Administration (FDA)

Bills named: S. 1695 (114th), H.R. 3020 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.